DNMT3A and acute myeloid leukemia: These findings indicate that combined therapy with SNDX-5613 and venetoclax is effective as in vivo therapy for AML harboring mutations in multiple genes, including mtNPM1, DNMT3A, IDH1, and mtFLT3, a set of co-mutations most commonly observed in AML with normal karyotype but known to be associated with poor prognosis.